(Q40378381)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16140040%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

title

The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16140040%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1 reference

Herpes simplex virus type 1

1 reference

Jeff L Hummel

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16140040%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

publication date

1 September 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16140040%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16140040%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16140040%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16140040%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

page(s)

1101-1110

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16140040%20AND%20SRC:MED&resulttype=core&format=json

Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant

6 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

The Pathogenicity of Ribonucleotide Reductase-Null Mutants of Herpes Simplex Virus Type 1 in Mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

Herpes simplex virus 1716, an ICP 34.5 null mutant, is unable to replicate in CV-1 cells due to a translational block that can be overcome by coinfection with SV40.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

Oncolytic viruses and cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

How cells respond to interferons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

Characterization of a gastric tumor cell line defective in MHC class I inducibility by both alpha- and gamma-interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma 134.5- mutants of her

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

Herpes simplex virus ICP0 mutants are hypersensitive to interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

Herpes simplex virus ICP0 and ICP34.5 counteract distinct interferon-induced barriers to virus replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

Defective translational control facilitates vesicular stomatitis virus oncolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

The herpes simplex virus ICP0 RING finger domain inhibits IRF3- and IRF7-mediated activation of interferon-stimulated genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

Regulation of the Interferon System: Evidence that Vero Cells have a Genetic Defect in Interferon Production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

Oncolytic herpes simplex virus vectors for cancer virotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

ICP0, a regulator of herpes simplex virus during lytic and latent infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

Progression to Malignancy in the Polyoma Middle T Oncoprotein Mouse Breast Cancer Model Provides a Reliable Model for Human Diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

Opinion: Comparative biology of mouse versus human cells: modelling human cancer in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

HSV-1 therapy of primary tumors reduces the number of metastases in an immune-competent model of metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

Destruction of nonimmunogenic mammary tumor cells by a fusogenic oncolytic herpes simplex virus induces potent antitumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

Signal transduction in mammary tumorigenesis: a transgenic perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

7 January 2021

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

Herpes simplex virus type 1 immediate-early protein ICP0 and is isolated RING finger domain act as ubiquitin E3 ligases in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

Cell-cycle checkpoints and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

Oncolytic herpes viruses as a potential mechanism for cancer therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

Herpes simplex virus triggers and then disarms a host antiviral response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

Innate cellular response to virus particle entry requires IRF3 but not virus replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533

An activity specified by the osteosarcoma line U2OS can substitute functionally for ICP0, a major regulatory protein of herpes simplex virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.533